Abstract 5336
Background
Lung cancer stem cells (CSCs) are a small subpopulation of cells with self-renewal, tumorigenic properties and the ability to grow to form tumorspheres in non-adherent conditions. Recently, the study on soluble molecules has been a new focus to understand the interaction between CSCs and tumor microenvironment. The aim of this work is to compare the release of cytokines between monolayer cells and tumorspheres of NSCLC cultures.
Methods
The study was performed on medium supernatant of cells from 8 NSCLC tumour patients samples and 10 cell lines (A549, H1650, H460, H23, H358, H2228, HCC827, PC9, H1993, SW900) grown in monolayer and tumorspheres at 2 different densities (104 and 105 cells/ml); supernatant was recollected at 12h and 24h. We analyzed 8 soluble factors with immunosuppressive (IL-4, IL-10, IL-13), and immunoregulatory (IL-6, IL-8, IL-17A, TNFa, IFN) capacity through sensitivity bead-based multiplex assay using the Millipore kit from the Luminex 100/200.
Results
IL-4, IL-6, IL-8, TNFa levels were detected in all samples while IFN, IL-10, IL-13, IL-17A were beyond the detectable range in adherents for most of cultures (Detection range [pg/ml] of IL-4: 1.83-7497.38, IL-6: 0.18-813.66, IL-8: 0.31-1042.75, TNFa: 0.43-1758.47, IFN: 0.61-2468.39, IL-10: 1.46-6056.85, IL-13: 0.24-1002.76, IL-17A: 0.73-3074.88). We observed significant differences in levels of IL-6, IL-13, IL-17A, TNFa, IFN between adherent cells and tumorspheres. Moreover, IL-4, IL-10, IL-13, IL-17A, IFN levels in tumorspheres were higher than monolayer. Otherwise, IL-6 and TNFa were secreted more in monolayer. IL-8 is the most secreted molecule in both adherents and tumorspheres by all cultures.
Conclusions
Our preliminary results suggest that high levels of IL-6 and IL-8 were detected in all samples. IL-8, IL-13, IL-17A and IFN secreted by lung CSCs could be involved in the modulation of the immune microenvironment. Additionally, adherent cells show increased levels of IL-6 and TNFa compared to tumorspheres, and IL-8, IL-4, IFN, IL-10, IL-13, IL-17A show the opposite. The next is to extend the cohort to validate our results and to study others immunoregulatory factors. Supported by grants from FEDER and PI12-02838 and PI15-00753 from ISCIII.
Clinical trial identification
Legal entity responsible for the study
Fundación de Investigación del Hospital General Universitario de Valencia.
Funding
Supported by grants from FEDER and PI12-02838 and PI15-00753 from ISCIII.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract